Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer
Malignant tumor cells are equipped with mechanisms that can help them escape the surveillance by host immune system. Immune checkpoint molecules can transduce coinhibitory signals to immunocompetent cells and exert immunosuppressive roles in antitumor immunity. Programmed death-1 (PD-1) and programm...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2016-11-01
|
| Series: | Therapeutic Advances in Gastroenterology |
| Online Access: | https://doi.org/10.1177/1756283X16658251 |
| _version_ | 1818539421245374464 |
|---|---|
| author | Xiaojun Liu Zhongxia Yang Olivier Latchoumanin Liang Qiao |
| author_facet | Xiaojun Liu Zhongxia Yang Olivier Latchoumanin Liang Qiao |
| author_sort | Xiaojun Liu |
| collection | DOAJ |
| description | Malignant tumor cells are equipped with mechanisms that can help them escape the surveillance by host immune system. Immune checkpoint molecules can transduce coinhibitory signals to immunocompetent cells and exert immunosuppressive roles in antitumor immunity. Programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) are the two important checkpoint molecules with great potential in targeted cancer therapy. Several antibodies targeting PD-1 and PD-L1 have been approved for clinical use. In this review, we focus on the recent development of targeting PD-1 and PD-L1 in gastric cancer (GC) therapy. |
| first_indexed | 2024-12-11T21:41:48Z |
| format | Article |
| id | doaj.art-4730c846628347129806d74b0bf0e9c8 |
| institution | Directory Open Access Journal |
| issn | 1756-283X 1756-2848 |
| language | English |
| last_indexed | 2024-12-11T21:41:48Z |
| publishDate | 2016-11-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Gastroenterology |
| spelling | doaj.art-4730c846628347129806d74b0bf0e9c82022-12-22T00:49:48ZengSAGE PublishingTherapeutic Advances in Gastroenterology1756-283X1756-28482016-11-01910.1177/1756283X16658251Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancerXiaojun LiuZhongxia YangOlivier LatchoumaninLiang QiaoMalignant tumor cells are equipped with mechanisms that can help them escape the surveillance by host immune system. Immune checkpoint molecules can transduce coinhibitory signals to immunocompetent cells and exert immunosuppressive roles in antitumor immunity. Programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) are the two important checkpoint molecules with great potential in targeted cancer therapy. Several antibodies targeting PD-1 and PD-L1 have been approved for clinical use. In this review, we focus on the recent development of targeting PD-1 and PD-L1 in gastric cancer (GC) therapy.https://doi.org/10.1177/1756283X16658251 |
| spellingShingle | Xiaojun Liu Zhongxia Yang Olivier Latchoumanin Liang Qiao Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer Therapeutic Advances in Gastroenterology |
| title | Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer |
| title_full | Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer |
| title_fullStr | Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer |
| title_full_unstemmed | Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer |
| title_short | Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer |
| title_sort | antagonizing programmed death 1 and programmed death ligand 1 as a therapeutic approach for gastric cancer |
| url | https://doi.org/10.1177/1756283X16658251 |
| work_keys_str_mv | AT xiaojunliu antagonizingprogrammeddeath1andprogrammeddeathligand1asatherapeuticapproachforgastriccancer AT zhongxiayang antagonizingprogrammeddeath1andprogrammeddeathligand1asatherapeuticapproachforgastriccancer AT olivierlatchoumanin antagonizingprogrammeddeath1andprogrammeddeathligand1asatherapeuticapproachforgastriccancer AT liangqiao antagonizingprogrammeddeath1andprogrammeddeathligand1asatherapeuticapproachforgastriccancer |